Table 1.
Baseline and Demographic Characteristics of Study Participants
| Total Patients (N = 26), n (%) | Arm A: Abiraterone (n = 12), n (%) | Arm B: Abiraterone + Dasatinib (n = 14), n (%) | |
|---|---|---|---|
| Median age at study entry, y (range) | 66.5 (55.6–85.3) | 66.4 (55.6–75.9) | 66.5 (55.7–85.3) |
| Race | |||
| Caucasian | 11 (42) | 6 (50) | 5 (36) |
| Hispanic | 9 (35) | 4 (33) | 5 (36) |
| Black | 3 (12) | 1 (8) | 2 (14) |
| Asian | 3 (12) | 1 (8) | 2 (14) |
| Prior therapy | |||
| Bicalutamide | 21 (81) | 8 (67) | 13 (93) |
| Ketoconazole | 1 (4) | 0 (0) | 1 (7) |
| PSA level at study entry, ng/mL | |||
| Median (range) | 19.8 (0.84–1387) | 22.2 (0.9–1387) | 19.8 (0.8–184.1) |
| ECOG PS | |||
| 0 | 22 (85) | 9 (75) | 13 (93) |
| 1–2 | 4 (15) | 3 (25) | 1 (7) |
| Disease site involvement at baseline | |||
| Lymph node only | 6 (23) | 2 (17) | 4 (29) |
| Bone only | 12 (46) | 8 (67) | 4 (29) |
| Soft tissue ± bone | 8 (31) | 2 (17) | 6 (43) |
| Radiographic progressive disease prior to study entry | |||
| No | 3 (12) | 1 (8) | 2 (14) |
| Yes | 23 (88) | 11 (92) | 12 (86) |
Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance status; PSA = prostate-specific antigen.